All In Biotech

Drug Trial Radar · NCT07370818

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

An Open-label, Dose-finding and Randomized Active-controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of JPI-547 With Bevacizumab Maintenance Therapy in Relapsed Ovarian Cancer Patients Previously Treated With PARP Inhibitor Maintenance Therapy and Responding to Last Platinum Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jan 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients

Conditions

  • Ovarian Cancer

Interventions

  • JPI-547Drug

    taking JPI-547

  • BevacizumabDrug

    administration Bevacizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum tolerated dose (MTD) and recommended dose (RD)(RP2D)Time frame: The dose-limiting toxicity evaluation window is 21 days
  2. Part B: Progression free survival(PFS)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 74 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.